{"id":1709,"date":"2025-02-21T13:08:04","date_gmt":"2025-02-21T13:08:04","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T18:39:31","modified_gmt":"2026-06-26T18:39:31","slug":"9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","title":{"rendered":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline"},"content":{"rendered":"\n<p><strong>Quebec City, February 21, 2025<\/strong>&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two Quebec-based biotech companies. This funding will accelerate the preclinical development of highly targeted, safer cancer therapies, leveraging artificial intelligence (AI) and structural biology to redefine drug discovery.<\/p>\n\n\n\n<p>The initiative is backed by a $1M grant from the Government of Quebec, awarded through CQDM\u2019s Partenar-IA program, in partnership with IVADO.<\/p>\n\n\n\n<p>This investment will allow 9Bio Therapeutics, Molecular Forecaster, and Aramis Biotechnologies to expand and validate their platforms:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>9Bio Therapeutics will mobilize its AI-guided structural biology platform to generate highly selective and effective antibodies for oncology applications.<\/li>\n\n\n\n<li>Molecular Forecaster will deploy its biophysics-based approach, bolstered by machine learning models, to generate small molecules specifically targeting tumor cells.<\/li>\n\n\n\n<li>Aramis Biotechnologies will manufacture antibodies using its flexible plant-based platform.<\/li>\n<\/ul>\n\n\n\n<p>While this collaboration brings together synergistic expertise, each company will fully retain its own intellectual property (IP), balancing collaborative development and independent value creation while advancing novel oncology solutions.<\/p>\n\n\n\n<p>\u201cThis partnership accelerates 9Bio\u2019s vision to leverage AI and structural biology for a new era of cancer therapeutics. We\u2019re not only expediting drug discovery \u2013 we are developing oncology medicines designed to maximize efficacy while minimizing side effects, ultimately improving patient outcomes,\u201d said Henrique de Carvalho, Co-Founder &amp; CEO, 9Bio Therapeutics.<\/p>\n\n\n\n<p><strong>A step toward the future of oncology therapies<\/strong><\/p>\n\n\n\n<p>Current oncology treatments often lead to significant side effects, with up to 32% of patients discontinuing treatment or opting for less effective alternatives (1). This collaboration aims to develop next-generation precision therapies that enhance patient outcomes while maximizing commercial viability and pipeline scalability.<\/p>\n\n\n\n<p><strong>Positioning 9Bio for rapid growth in oncology innovation<\/strong><\/p>\n\n\n\n<p>9Bio\u2019s AI-guided structural biology platform is designed to overcome key limitations of existing biologics, enabling:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reduced off-tumor binding, minimizing side effects<\/li>\n\n\n\n<li>Improved bioavailability, enhancing therapeutic efficacy<\/li>\n\n\n\n<li>Novel therapeutic modalities, unlocking new treatment opportunities<\/li>\n<\/ul>\n\n\n\n<p>\u201cBy integrating AI-driven structural biology with advanced molecular modeling, 9Bio is transforming the way oncology biologics are designed. Our technology enables the precise engineering of therapeutic molecules that selectively target tumors while minimizing off-target effects, addressing a critical challenge in cancer treatment,\u201d said Philipe Gobeil, Co-Founder, President &amp; CSO, 9Bio Therapeutics.<\/p>\n\n\n\n<p>Read the official CQDM press release&nbsp;<a href=\"https:\/\/cqdm.org\/en\/news-and-events\/cqdm-ivado-and-three-quebec-based-companies-invest-2m-to-accelerate-the-development-of-highly-targeted-less-toxic-cancer-therapies-using-ai\/\" rel=\"noreferrer noopener\" target=\"_blank\"><u>here<\/u><\/a>.<\/p>\n\n\n\n<p><strong>Reference: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><br><a>(1) Holmstroem et al., Eur J. Cancer, 2024<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><strong>About 9Bio Therapeutics<\/strong><br><br>9Bio Therapeutics is a biotech company committed to developing innovative oncology therapeutics. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. Using this approach, we generate medicines with specificity for tumors that spare healthy tissues, improving safety, efficacy, and opening the door to previously underexploited therapeutic modalities. Our pipeline includes three discovery-stage therapies: an antibody-drug conjugate (ADC) targeting tumor cells, an ADC targeting tumor-subverted immune cells, and an engineered cytokine.<\/p>\n\n\n\n<p><strong>About Aramis Biotechnologies<\/strong><br><br>Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in plant-based production of innovative vaccines. As a majority employee-owned company, Aramis\u2019 ambition is to develop innovative and sustainable solutions to current and future public health challenges.\u202fThe Aramis\u2019 team is grateful for the support from Innovation, Sciences and Economic Development Canada, from the City of Quebec and from its group of private investors. Learn more at&nbsp;<a href=\"https:\/\/aramisbiotechnologies.com\/en\/\" rel=\"noreferrer noopener\" target=\"_blank\">https:\/\/aramisbiotechnologies.com\/en\/<\/a>.<\/p>\n\n\n\n<p><strong>About CQDM<\/strong><\/p>\n\n\n\n<p><em>Biopharma Innovation Facilitator<\/em><br>CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate collaborative multi-stakeholder research and development aimed at accelerating the translation or transformation of innovative technologies into solutions to unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, consult our website&nbsp;&nbsp;<a href=\"https:\/\/cqdm.org\/en\/\">https:\/\/cqdm.org\/en\/<\/a>&nbsp;and join us on Twitter\/X&nbsp;<a href=\"https:\/\/x.com\/CQDM_Canada\" rel=\"noreferrer noopener\" target=\"_blank\">@CQDM_Canada<\/a>&nbsp;and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/cqdm\/\" rel=\"noreferrer noopener\" target=\"_blank\">LinkedIn.<\/a><\/p>\n\n\n\n<p><strong>Partenar-IA&nbsp;<\/strong>is a program providing direct support to Quebec companies for collaborative biopharmaceutical R&amp;D projects based on artificial intelligence and applicable to the biopharmaceutical sector.<\/p>\n\n\n\n<p><strong>About IVADO<\/strong><\/p>\n\n\n\n<p>IVADO is an interdisciplinary, cross-sectoral research and knowledge mobilization consortium whose mission is to develop and promote a robust, reasoning and responsible AI. Led by Universit\u00e9 de Montr\u00e9al with four university partners (Polytechnique Montr\u00e9al, HEC Montr\u00e9al, Universit\u00e9 Laval and McGill University), IVADO brings together research centers, government bodies and industry members to co-build ambitious cross-sectoral initiatives with the goal of fostering a paradigm shift for AI and its adoption. For more information, please visit our website at&nbsp;<a href=\"https:\/\/ivado.ca\/en\/\" rel=\"noreferrer noopener\" target=\"_blank\">https:\/\/ivado.ca\/en\/<\/a>.<\/p>\n\n\n\n<p><strong>About Molecular Forecaster<\/strong><br><br>Molecular Forecaster Inc. (MFI) is helping organizations make smarter decisions in small molecule drug design. MFI uses a highly collaborative research-as-a-service to transform data into insight to accelerate preclinical pharmaceutical programs around the world. The company is a go-to partner in small molecule drug design, combining proprietary tools and technology, expertise and know-how, and an all-in approach to collaboration to advance only the best shots on goal. Learn more at&nbsp;<a href=\"https:\/\/molecularforecaster.com\/\" rel=\"noreferrer noopener\" target=\"_blank\">https:\/\/molecularforecaster.com\/<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/9bio.ca\/news\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/\">Read the original press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Quebec City, February 21, 2025&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1697,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"company":[89],"class_list":["post-1709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-portfolio-companies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>9Bio Therapeutics secures strategic funding to advance its oncology pipeline | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline | adMare\" \/>\n<meta property=\"og:description\" content=\"Quebec City, February 21, 2025&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-21T13:08:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T18:39:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline\",\"datePublished\":\"2025-02-21T13:08:04+00:00\",\"dateModified\":\"2026-06-26T18:39:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\"},\"wordCount\":832,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"articleSection\":[\"Portfolio Companies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\",\"name\":\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"datePublished\":\"2025-02-21T13:08:04+00:00\",\"dateModified\":\"2026-06-26T18:39:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/accelmay2024en-2-1740158243.png\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/news-events\\\/news-insights\\\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/en\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"9Bio Therapeutics secures strategic funding to advance its oncology pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/en\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline | adMare","og_description":"Quebec City, February 21, 2025&nbsp;\u2013 9Bio Therapeutics, a biotech company pioneering next-generation oncology therapeutics, is pleased to announce its participation in a $2M project initiative alongside CQDM, IVADO, and two [&hellip;]","og_url":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","og_site_name":"adMare","article_published_time":"2025-02-21T13:08:04+00:00","article_modified_time":"2026-06-26T18:39:31+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline","datePublished":"2025-02-21T13:08:04+00:00","dateModified":"2026-06-26T18:39:31+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/"},"wordCount":832,"publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","articleSection":["Portfolio Companies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","url":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/","name":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","datePublished":"2025-02-21T13:08:04+00:00","dateModified":"2026-06-26T18:39:31+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2025\/06\/accelmay2024en-2-1740158243.png","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/news-events\/news-insights\/9bio-therapeutics-secures-strategic-funding-to-advance-its-oncology-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/en\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/en\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/en\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"9Bio Therapeutics secures strategic funding to advance its oncology pipeline"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/en\/#website","url":"https:\/\/admarebio.com\/en\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/en\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/en\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/comments?post=1709"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1709\/revisions"}],"predecessor-version":[{"id":1710,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/posts\/1709\/revisions\/1710"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media\/1697"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/media?parent=1709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/categories?post=1709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/tags?post=1709"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/en\/wp-json\/wp\/v2\/company?post=1709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}